Phase I/II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme.
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Vorinostat (Primary) ; Isotretinoin; Temozolomide
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 22 Aug 2024 Status changed from active, no longer recruiting to discontinued due to no sponsor funding
- 29 Oct 2020 Planned End Date changed from 30 Apr 2024 to 20 Apr 2024.
- 29 Oct 2020 Planned primary completion date changed from 30 Apr 2024 to 20 Apr 2024.